As cited by the research report titled ‘Global Anti-obesity Drugs Market Size study, by Mechanism of Action (Peripherally Acting Drugs, and Centrally Acting Drugs), by Drug Type (Prescription Drugs, and OTC Drugs)and Regional Forecasts 2020-2027’, available with Market Study Report, global anti-obesity drugs market was worth USD 1.39 billion in 2019 and is projected to grow with a CAGR of 15% over 2020-2027 to accumulate USD 4.25 billion by the end of study duration.
 

Changing diets leading to consumption of unhealthy food, rising disposable incomes coupled with progressive medical research are the factors acting as drivers for the growth of global anti-obesity drugs market.
 

As per Trust for America's Health, the adult obesity rate in the U.S. reached 42.4%, in 2020, crossing the 40% mark for the first time, warning of obesity crisis in the country. Since 2008, the national obesity rate has increased by around 26%.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3357871/
 

For those unaware, anti-obesity drugs help in reducing body fat by either increasing calorie intake or decreasing appetite. Consumption of fast foods and lack of exercise is expected to aggravate the number of obese patients worldwide, thus boosting the demand for anti-obesity therapeutics.
 

However, high costs of the drugs is a factor acting as a restraint to the growth of global anti-obesity drugs market.
 

Based on mechanism of action, worldwide anti-obesity drugs marketspace is segmented into centrally acting drugs, and peripherally acting drugs. Speaking of drug type, the industry sphere is divided into OTC drugs, and prescription drugs.
 

Geographically, Asia Pacific, Europe, North America, and Latin America are major revenue generators for worldwide anti-obesity drugs market. Of these, North America is projected to be a major growth hub for the market over 2020-2027, owing to increasing obese population, and high spending on healthcare.
 

Whereas, Asia Pacific market is reckoned to grow momentously over the forecast period, on account of increasing population and rising disposable incomes.
 

Notable players in global anti-obesity drugs industry include GlaxoSmithKline plc, Orexigen Therapeutics Inc., Novo Nordisk A/S, Eisai Co. Ltd., Merck & Co. Inc., Rhythm Pharmaceuticals Inc., Cadila Healthcare Limited, Takeda Pharmaceutical Company Limited, Arena Pharmaceuticals Inc., and Boehringer Ingelheim.